Corpus overview


MeSH Disease

Leukemia (6)

Disease (4)

Infections (3)

Pneumonia (2)

Death (2)

Human Phenotype


    displaying 1 - 7 records in total 7
    records per page

    R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes

    Authors: Masateru Takahashi; Muhammad Tehseen; Rahul Salunke; Etsuko Takahashi; Sara Mfarrej; Mohamed A. Sobhy; Fatimah Alhamlan; Sharif Hala; Gerardo R. Mandujano; Ahmed A. Al-Qahtani; Fadwa S. Alofi; Afrah Alsomali; Anwar M. Hashem; Asim Khogeer; Naif A. M. Almontashiri; Jae Man Lee; Hiroaki Mon; Kosuke Sakashita; Mo Li; Takahiro Kusakabe; Arnab Pain; Samir M. Hamdan

    doi:10.1101/2020.07.31.20165704 Date: 2020-08-04 Source: medRxiv

    One-step RT-qPCR is the most widely applied method for COVID-19 diagnostics. Designing in-house one-step RT-qPCR kits is restricted by the patent-rights for the production of enzymes and the lack of information about the components of the commercial kits. Here, we provide a simple, economical, and powerful one-step RT-qPCR kit based on patent-free, specifically-tailored versions of Moloney Murine Leukemia MESHD Leukemia HP Virus Reverse Transcriptase and Thermus aquaticus DNA polymerase termed the R3T (Rapid Research Response Team) One-step RT-qPCR. Our kit was routinely able to reliably detect as low as 10 copies of the synthetic RNAs of the SARS-CoV-2. More importantly, our kit successfully detected COVID-19 in clinical samples of broad viral titers with similar reliability and selectivity as that of the Invitrogen SuperScript III Platinum One-step RT-qPCR and TaqPath 1-Step RT-qPCR kits. Overall, our kit has shown robust performance SERO in both of laboratory settings and the Saudi Ministry of Health-approved testing facility.

    Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia MESHD Leukemia HP Virions

    Authors: Yue Zheng; Erin Therese Larragoite; Juan Lama; Isabel Cisneros; Julio C. Delgado; Patricia Slev; Jennifer Rychert; Mayte Coiras; Matthew Rondina; Adam Mitchell Spivak; Vicente Planelles

    doi:10.1101/2020.07.17.207563 Date: 2020-07-18 Source: bioRxiv

    Antibody SERO neutralization is an important prognostic factor in many viral diseases MESHD. To easily and rapidly measure titers of neutralizing antibodies SERO in serum SERO or plasma SERO, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia MESHD leukemia HP virus capsids and a modified minimal MLV genome encoding firefly luciferase. These pseudovirions provide a practical means of assessing immune responses under laboratory conditions consistent with biocontainment level 2.

    Targeting heparan sulfate proteoglycan-assisted endocytosis as a COVID-19 therapeutic option

    Authors: Qi Zhang; Catherine Chen; Manju Swaroop; Miao Xu; Lihui Wang; Juhyung Lee; Manisha Pradhan; Min Shen; Zhiji Luo; Yue Xu; Wenwei Huang; Wei Zheng; Yihong Ye

    doi:10.1101/2020.07.14.202549 Date: 2020-07-14 Source: bioRxiv

    Drugs capable of blocking the infectious cycle of the coronavirus SARS-CoV-2 are urgently needed to tackle the ongoing COVID-19 pandemic. To this end, the cell entry of SARS-CoV-2, initiated by the binding of the viral Spike (S) protein to human ACE2, has emerged as an attractive drug repurposing target. Here we use murine leukemia MESHD leukemia HP viruses pseudotyped with Spike from SARS-CoV or SARS-CoV-2 to demonstrate that ACE2-mediated coronavirus entry can be mitigated by heparin, a heparan sulfate-related glycan, or by genetic ablation of biosynthetic enzymes for the cell surface heparan sulfate proteoglycans (HSPGs). A drug repurposing screen targeting HSPG-dependent endocytosis identifies pharmacologically active endocytosis inhibitors that also abrogate coronavirus cell entry. Among them, Mitoxantrone (EC50=~10 nM) targets HSPGs directly, whereas Sunitinib and BNTX disrupt the actin network to impair HSPG-assisted viral entry. Gene expression profiling suggests potential combination regimens that optimally target HSPG-dependent viral entry. Altogether, our study establishes HSPGs as an assisting factor for ACE2 in endocytosis-mediated coronavirus entry and identifies drugs that can be repurposed to target this important stage in the viral life cycle.

    Cancer inpatient with COVID-19: a report from the Brazilian National Cancer Institute

    Authors: Andreia C de Melo; Luiz Claudio S Thuler; Jesse L da Silva; Lucas Z de Albuquerque; Ana Carla Pecego; Luciana O.R. Rodrigues; Magda S da Conceicao; Marianne M Garrido; Gelcio L Mendes; Ana Cristina M Pereira; Marcelo A Soares; Joao P.B. Viola; - INCA COVID-19 Task Force

    doi:10.1101/2020.06.27.20141499 Date: 2020-06-29 Source: medRxiv

    Brazil has been recording a frightening exponential curve of confirmed cases TRANS of SARS-CoV-2 infection MESHD. Cancer patients with COVID-19 are likely to have a greater risk of complications and death MESHD. A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR method. The mean age TRANS was 55.3 years (SD 21.1). The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma MESHD lymphoma HP (20 [11%]) and leukemia MESHD leukemia HP (10 [5.5%]) predominated. The most common complications were respiratory failure HP (70 [38.7%]), septic shock MESHD shock HP (40 [22.1%]) and acute kidney injury MESHD acute kidney injury HP (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. By multivariate analysis, cases with admission due to symptoms of COVID-19 (p = 0.027) and with two or more metastatic sites (p <0.001) showed a higher risk of COVID-19-specific death MESHD. This is the first study in a cohort of Brazilian cancer patients with COVID-19. The rates of complications and COVID-19-specific death MESHD were significantly high. Our data prompts urgent and effective public policies for this group of especially vulnerable patients.

    Swarm Learning as a privacy-preserving machine learning approach for disease MESHD classification

    Authors: Stefanie Warnat-Herresthal; Hartmut Schultze; Krishna Prasad Lingadahalli Shastry; Sathyanarayanan Manamohan; Saikat Mukherjee; Vishesh Garg; Ravi Sarveswara; Kristian Haendler; Peter Pickkers; N Ahmad Aziz; Sofia Ktena; Christian Siever; Michael Kraut; Milind Desai; Bruno Monet; Maria Saridaki; Charles Martin Siegel; Anna Drews; Melanie Nuesch-Germano; Heidi Theis; Mihai G Netea; Fabian J Theis; Anna C Aschenbrenner; Thomas Ulas; Monique M.B. Breteler; Evangelos J Giamarellos-Bourboulis; Matthijs Kox; Matthias Becker; Sorin Cheran; Michael S Woodacre; Eng Lim Goh; Joachim L. Schultze; - German COVID-19 OMICS Initiative (DeCOI)

    doi:10.1101/2020.06.25.171009 Date: 2020-06-26 Source: bioRxiv

    Identification of patients with life-threatening diseases MESHD including leukemias MESHD leukemias HP or infections MESHD such as tuberculosis MESHD and COVID-19 is an important goal of precision medicine. We recently illustrated that leukemia MESHD leukemia HP patients are identified by machine learning (ML) based on their blood SERO transcriptomes. However, there is an increasing divide between what is technically possible and what is allowed because of privacy legislation. To facilitate integration of any omics data from any data owner world-wide without violating privacy laws, we here introduce Swarm Learning (SL), a decentralized machine learning approach uniting edge computing, blockchain-based peer-to-peer networking and coordination as well as privacy protection without the need for a central coordinator thereby going beyond federated learning. Using more than 14,000 blood SERO transcriptomes derived from over 100 individual studies with non-uniform distribution of cases and controls and significant study biases, we illustrate the feasibility of SL to develop disease MESHD classifiers based on distributed data for COVID-19, tuberculosis MESHD or leukemias MESHD leukemias HP that outperform those developed at individual sites. Still, SL completely protects local privacy regulations by design. We propose this approach to noticeably accelerate the introduction of precision medicine.

    Pathological Study of the 2019 Novel Coronavirus Disease MESHD (COVID-19) through Post-Mortem Core Biopsies

    Authors: Sufang Tian; Yong Xiong; Huan Liu; Li Niu; Jianchun Guo; Meiyan Liao; Shu-Yuan Xiao

    id:10.20944/preprints202003.0311.v1 Date: 2020-03-20 Source:

    Data on pathologic changes of the 2019 novel coronavirus disease MESHD (COVID-19) are scarce. To gain knowledge about the pathology that may contribute to disease progression MESHD and fatality, we performed post-mortem needle core biopsies of lung, liver, and heart in four patients who died of COVID-19 pneumonia MESHD pneumonia HP. The patients’ ages TRANS ranged from 59 to 81, including 3 males TRANS and 1 female TRANS. Each patient had at least one underlying disease MESHD, including immunocompromised status (chronic lymphocytic leukemia MESHD leukemia HP and renal transplantation) or other conditions ( cirrhosis HP, hypertension MESHD hypertension HP, and diabetes). Time from disease MESHD onset to death MESHD ranged from 15 to 52 days. All patients had elevated white blood SERO cell counts, with significant rise toward the end, and all had lymphocytopenia except for the patient with leukemia MESHD leukemia HP. Histologically, the main findings are in the lungs, including injury to the alveolar epithelial cells, hyaline membrane formation, and hyperplasia MESHD of type II pneumocytes, all components of diffuse alveolar damage. Consolidation by fibroblastic proliferation with extracellular matrix and fibrin forming clusters in airspaces is evident. In one patient, the consolidation consists of abundant intra-alveolar neutrophilic infiltration, consistent with superimposed bacterial bronchopneumonia MESHD. The liver exhibits mild lobular infiltration by small lymphocytes, and centrilobular sinusoidal dilation. Patchy necrosis MESHD is also seen. The heart shows only focal mild fibrosis MESHD and mild myocardial hypertrophy MESHD, changes likely related to the underlying conditions. In conclusion, the post-mortem examinations show advanced diffuse alveolar damage, as well as superimposed bacterial pneumonia MESHD pneumonia HP in some patients. Changes in the liver and heart are likely secondary or related to the underlying diseases MESHD.

    Clinical characteristics of four cancer patients with SARS-CoV-2 infection MESHD in Wuhan, China

    Authors: Shihui Song; Zhiyong Ma; Tielong Chen; Liping Deng; Yongxi Zhang; Pingzheng Mo; Shicheng Gao; Wenjia Hu; Yong Xiong

    doi:10.21203/ Date: 2020-03-19 Source: ResearchSquare

    Background: The severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) led to the outbreak of pneumonia MESHD pneumonia HP in Wuhan, and rapidly spread throughout China. The virus is highly infectious and can infect individuals in the community, including patients in the hospital. Patients with cancer might be susceptible to the viral infection MESHD because of the immunosuppressive state cause by therapies on tumors. Case presentation: We present the clinical features of four cancer patients who were infected with SARS-CoV-2 in the past month in our hospital. One patient with uncontrolled chronic B cell lymphocytic leukemia MESHD leukemia HP and many other underlying diseases MESHD was killed by the virus, and the other three patients survived. Nearly all patients showed a decrease in lymphocytes including total CD3+ T cells, B cells, and natural killer cells after infection MESHD of the virus. Conclusion: This report suggests that the treatment of SARS-CoV-2 infection MESHD in cancer patients is challenged by the immunosuppressive state of these patients under chemotherapy or surgery.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.